|
1) Trede M, Richter A, Wendl K. Personal observations, opinions, and approaches to cancer of the pancreas and the periampullary area. Surg Clin North Am. 2001; 81: 595-610
|
|
|
|
2) Traverso LW. Pancreatic cancer: surgery alone is not sufficient. Surg Endosc. 2006; Suppl 2: S446-9
|
|
|
|
|
|
3) 今泉俊秀, 飛田浩輔, 堂脇昌一, 他. 脈間合併切除を伴う膵癌切除術の意義. 消化器外科. 2005; 28: 189-99
|
|
|
|
|
4) Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic cancer Registry in Japan: 20 years of experience. Pancreas. 2004; 28: 219-30
|
|
|
|
|
|
5) 梛野正人, 二村雄次. 膵癌治療─最近の動向 拡大手術は生存率向上に寄与するか？ 日外会誌. 2006; 107: 173-6
|
|
|
|
|
|
6) 日本膵臓学会膵癌診療ガイドライン作成小委員会編. 膵癌診療ガイドライン2006年版. 東京: 金原出版; 2006
|
|
|
|
|
|
7) Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads ＋ 5-fluorouracil), and high dose radiation ＋ 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981; 48: 1705-10
|
|
|
|
|
|
8) Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988; 80: 751-5
|
|
|
|
|
|
9) Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006. p. 4008
|
|
|
|
|
|
10) National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in OncologyTM: Pancreatic Adenocarcinoma. V. 1. 2007. http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pd
|
|
|
|
|
|
11) Imamura M, Doi R, Imaizumi T, et al. A randomized multicenter trial comparing resection and radiochemotherapy for respectable locally invasive pancreatic cancer. Surgery. 2004; 136: 1003-11
|
|
|
|
|
|
12) 羽鳥 隆, 高崎 健, 今泉俊秀, 他. 膵癌に対する拡大手術の適応と限界. 消化器外科. 1997; 21: 1071-8
|
|
|
|
|
|
13) 今村正之, 細谷 亮. 膵臓癌の進展様式に応じた手術術式. 肝胆膵. 1997; 34: 367-75
|
|
|
|
|
|
14) Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg. 1998; 228: 508-17
|
|
|
|
|
|
15) Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adeno-carcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002; 236: 355-66. discussion 366- 8
|
|
|
|
|
|
16) Riall TS, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adeno-carcinomapart 3: update on 5-year survival. J Gastrointest Surg. 2005; 9: 1191-204
|
|
|
|
|
|
17) Snady H, Bruckner H, Cooperman A, et al. Survival advantage of combined chemo-radiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. Cancer. 2000; 89: 314-27
|
|
|
|
|
|
18) 木村 理. 癌外科治療の標準化に向けての展望. 8. 膵癌. 日外会誌. 2003; 104: 412-21
|
|
|
|
|
|
19) Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267-77
|
|
|
|
|
|
20) Takamori H, Hiraoka T, Kanemitsu K, et al. Identification of prognostic factors associated with early mortality after surgical resection for pancreatic cancer under-analysis of cumulative survival curve. World J Surg. 2006; 30: 213-8
|
|
|
|
|
|
21) 石川 治, 大東弘明, 江口英利, 他. 膵癌治療最近の動向 術前術後の化学放射線療法. 日外会誌. 2006; 107: 182-6
|
|
|
|
|
|
22) Ohigashi H, Ishikawa O, Eguchi H, et al. Feasibility and efficacy of combination therapy with preoperative and postoperative chemo-radiation, extended pancreatectomy, and post-operative liver perfusion chemotherapy for locally advanced cancer of the pancreatic head. Ann Surg Oncol. 2005; 12: 629-36
|
|
|
|
|
|
23) Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 1200-10
|
|
|
|
|
|
24) 飛田浩輔, 今泉俊秀, 堂脇昌一, 他. 局所進行膵癌に対する外科治療の現況. 外科治療. 2007; 96: 304-9
|
|
|
|
|
|
25) Nakamura K, Yamaguchi T, Ishihara T, et al. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2006; 94: 1575-9
|
|
|
|
|
|
26) Ueno H, Okusaka T, Ikeda M, et al. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology. 2005; 69: 421-7. Epub 2005 Nov 25
|
|
|
|
|
|
27) Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 1
|
|
|
|
|